ITGB1
Integrin beta-1
As of the edition of 20 October 2026, ITGB1 (integrin beta-1, UniProt P05556) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P05556
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 22
- Disease areas
- Cancer
- Registered trials of its drugs
- 2
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| MINT-1526A | Went quiet | Phase 1 | none listed |
| OS2966 | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Roche | Route A |
| OncoSynergy | Route A |
The other 0 companies at ITGB1
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at ITGB1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.